Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Habermann

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Mayo Clinic Proceedings|April 1, 1994
Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosisT G Call, R L Phyliky, P Noël, et al.
Mayo Clinic Proceedings|November 1, 1987
Immunofluorescence labeling indices in myeloma and related monoclonal gammopathiesP R Greipp, T E Witzig, N J Gonchoroff, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 28, 2001
Orbital lymphoma: radiotherapy outcome and complicationsS L Stafford, T F Kozelsky, J A Garrity, et al.
American Journal of Epidemiology|June 16, 1999
Blood transfusion and risk of non-Hodgkin's lymphomaE K Maguire-Boston, V Suman, S J Jacobsen, et al.
Leukemia & Lymphoma|June 28, 2001
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)P H Wiernik, T Leong, M M Oken, et al.
Leukemia & Lymphoma|April 7, 2000
Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older womenA S Parker, J R Cerhan, F Dick, et al.
Blood|November 24, 1999
A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensityL I Gordon, M Young, E Weller, et al.
Leukemia & Lymphoma|October 1, 1994
Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphomaJ P Colgan, J Andersen, T M Habermann, et al.
Hematologic Pathology|January 1, 1991
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling indexP Beauregard, T E Witzig, P J Kurtin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 1995
Pretransplantation assessment of the risk of lymphoproliferative disorderR C Walker, W F Marshall, J G Strickler, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Mayo Clinic Proceedings|April 1, 1994
Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosisT G Call, R L Phyliky, P Noël, et al.
Mayo Clinic Proceedings|November 1, 1987
Immunofluorescence labeling indices in myeloma and related monoclonal gammopathiesP R Greipp, T E Witzig, N J Gonchoroff, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 28, 2001
Orbital lymphoma: radiotherapy outcome and complicationsS L Stafford, T F Kozelsky, J A Garrity, et al.
American Journal of Epidemiology|June 16, 1999
Blood transfusion and risk of non-Hodgkin's lymphomaE K Maguire-Boston, V Suman, S J Jacobsen, et al.
Leukemia & Lymphoma|June 28, 2001
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)P H Wiernik, T Leong, M M Oken, et al.
Leukemia & Lymphoma|April 7, 2000
Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older womenA S Parker, J R Cerhan, F Dick, et al.
Blood|November 24, 1999
A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensityL I Gordon, M Young, E Weller, et al.
Leukemia & Lymphoma|October 1, 1994
Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphomaJ P Colgan, J Andersen, T M Habermann, et al.
Hematologic Pathology|January 1, 1991
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling indexP Beauregard, T E Witzig, P J Kurtin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 1995
Pretransplantation assessment of the risk of lymphoproliferative disorderR C Walker, W F Marshall, J G Strickler, et al.
Pageof 10